

Mortality among adults living with HIV treated for tuberculosis based on positive, negative, or no bacteriologic test results for tuberculosis: the IeDEA consortium

John M Humphrey^{1*}, Philani Mpofu², April C. Pettit^{3,4}, Beverly Musick², E. Jane Carter⁵,
Eugene Messou^{6,7}, Olivier Marcy^{6,8}, Brenda Crabtree-Ramirez⁹, Marcel Yotebieng¹⁰, Kathryn
Anastos¹¹, Timothy R. Sterling^{3,4}, Constantin Yiannoutsos², Lameck Diero¹², Kara Wools-
Kaloustian¹, International Epidemiology Databases to Evaluate AIDS (IeDEA) Consortium[^]

¹ Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States

² Department of Biostatistics, Indiana University Fairbanks School of Public Health, Indianapolis, IN, United States

³ Vanderbilt University Medical Center, Nashville, TN, United States

⁴ Vanderbilt Tuberculosis Center, Nashville, TN, United States

⁵ Department of Medicine, Brown University School of Medicine, Providence, RI, United States

⁶ University of Bordeaux, Centre INSERM U1219, Bordeaux Population Health, Bordeaux, France

⁷ Centre de Prise en charge de Recherche et de Formation (Aconda-CePReF), Abidjan, Côte d'Ivoire

⁸ Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia

⁹ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

¹⁰ The Ohio State University, College of Public Health, Columbus, OH, United States

¹¹ Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States

¹² Department of Medicine, Moi University College of Health Sciences, Eldoret, Kenya

* Corresponding author

E-mail: humphrjm@iu.edu

[^] Membership in the IeDEA consortium for the participating programs is provided in the Supporting Information (S8 Table).

Short title: Mortality among adults with HIV treated for TB

Abstract

Background

In resource-constrained settings, people living with HIV (PLWH) treated for tuberculosis (TB) despite negative bacteriologic tests have a higher mortality than those treated with positive tests. Many PLWH are treated without bacteriologic testing; their mortality compared to those with bacteriologic testing is uncertain.

Methods

We conducted an observational cohort study among PLWH ≥ 15 years of age who initiated TB treatment at clinical sites affiliated with four regions of the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium from 2012-2014: Caribbean, Central and South America, and Central, East, and West Africa. The primary exposure of interest was the TB bacteriologic test status at TB treatment initiation: positive, negative, or no test result. The hazard for death in the 12 months following TB treatment initiation was estimated using the Cox proportional hazard model, adjusted for patient- and site-level factors. Missing covariates were multiply imputed.

Results

Among 2,091 PLWH included, the median age at TB treatment initiation was 36 years, 44% were female, 53% had CD4 counts ≤ 200 cells/mm³, and 52% were on antiretroviral treatment (ART). Compared to patients with positive bacteriologic tests, the adjusted hazard for death was higher among patients with no test results (HR 1.56, 95% CI 1.08-2.26) but not different than

those with negative tests (HR 1.28, 95% CI 0.91-1.81). Older age was also associated with a higher hazard for death, while being on ART, having a higher CD4 count, West Africa region, and tertiary facility level were associated with lower hazards for death.

Conclusion

PLWH treated for TB with no bacteriologic test results were more likely to die than those treated with positive tests, underscoring the importance of TB bacteriologic diagnosis in resource-constrained settings. Research is needed to understand the causes of death among PLWH treated for TB in the absence of positive bacteriologic tests.

Introduction

Although tuberculosis (TB) accounted for 300,000 deaths among people living with HIV (PLWH) in 2017, diagnosing TB in resource-limited settings remains a challenge [1]. In 2017, only 56% of the 5.5 million pulmonary TB cases reported to the World Health Organization (WHO) globally were bacteriologically confirmed (i.e. positive for smear microscopy, culture, or nucleic acid amplification test [NAAT]) [1]. Among studies reporting the autopsy prevalence of TB in HIV-related deaths, TB was prevalent in 37% of deaths, but in half of those cases, TB was not diagnosed by the time of death [2]. The rollout of nucleic acid amplification tests (NAAT) such as the Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA), which are more sensitive and specific than smear microscopy, has helped close this diagnostic gap [3]. However, limited impact on mortality has been observed with the use of Xpert MTB/RIF, in part due to high baseline rates of empiric TB treatment (i.e. based on clinical symptoms or radiographic signs) in high TB burden settings [3-5]. A better understanding of the risk of death among PLWH in the context of varying TB test results, or the absence of TB testing, is needed to inform the management of PLWH treated for TB in resource-limited settings where the risk of TB is high.

Acquiring a bacteriologic diagnosis of TB in resource-limited settings can be hampered by economic, clinical and test-related factors. Despite recent increases in TB diagnostic test coverage in sub-Saharan Africa, smear microscopy and culture is estimated to be available at only 1.4 and 0.7 laboratories per 100,000 population, respectively [6, 7]. Many labs in resource-constrained settings suffer from weak supply systems, outdated equipment, poor quality control, and insufficient staffing [6, 8-10]. Smear microscopy for acid-fast bacilli (AFB) is often the only TB test available in such settings but it is poorly sensitive among PLWH, with 30-60% of

pulmonary TB cases reported to be smear negative [11-13]. Clinicians may not order bacteriologic testing for TB among PLWH due to lack of knowledge about TB (or conversely, knowledge of the limitations of smear microscopy), or in cases of suspected extrapulmonary TB requiring invasive tissue sampling that is not feasible to perform [5, 8, 14, 15]. Patients may not be able to produce a sputum sample for bacteriologic testing or access TB testing sites (e.g. for serial sputum collection) due to the distance or cost of transport [8, 16, 17].

Empiric TB treatment in PLWH, either because a bacteriologic test was negative or no test was performed, is thus common in resource-limited settings [4, 5, 18-20]. However, mortality in the absence of TB bacteriologic testing is not well defined [21-24]. The objective of this study was to describe the characteristics and risk of death among PLWH treated for TB in the context of positive, negative, or no TB bacteriologic test results.

Materials and Methods

Study setting and patient population

This observational cohort study utilized data previously collected from PLWH who were enrolled in HIV care programs affiliated with four participating regions of the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium: Caribbean, Central and South America (CCASAnet), and Central, East, and West Africa [25]. IeDEA is a National Institutes of Health (NIH)-funded consortium that pools and harmonizes baseline and follow-up patient data collected in the context of routine care [26]. All participating facilities provided standard of care HIV and TB treatment services per their respective national guidelines. The study population included all PLWH ≥ 15 years of age who initiated TB treatment between January 2012 and

December 2014. Patients were excluded if an alternative diagnosis was established and TB therapy was stopped. Recurrent TB cases within the study period were excluded (n = 41), so a patient could not contribute more than one TB case. Patients receiving a drug-resistant TB treatment regimen were also excluded, which was defined according to WHO criteria as any injectable agent (except streptomycin), fluoroquinolones, or oral bacteriostatic agent (e.g. para-aminosalicylic acid, ethionamide, cycloserine) [27]. The reporting of this study conforms to the STROBE statement (S1 Table) [28].

Ethics statement

Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approval for this study was obtained by each of the local IeDEA sites as well as from the Indiana University IRB (S2 Table).

Data management

TB cases were identified at participating IeDEA sites through review of local TB registries by site staff. A standardized, electronic case report form developed in Research Electronic Data Capture (REDCap) and available in English and French was used to collect medical record data [29]. Data entry into case report forms was conducted from January 2012 through January 2016 by local IeDEA investigators following medical record review. Patient-level HIV data were obtained from the IeDEA regional HIV care and treatment data repositories for all patients with completed case report forms. Site-level data were obtained from surveys of antiretroviral treatment (ART) sites participating in IeDEA conducted between March 1 and July 1, 2012 [30, 31]. Routine audits were performed to ensure data quality throughout data collection. Regional

IeDEA data were transferred to the IeDEA-East Africa Regional Data Center where they were merged, and additional data quality assessments were undertaken before analysis.

Study definitions

Adult patients were defined as individuals ≥ 15 years of age to be consistent with WHO and other national and regional TB programs [32, 33]. The primary exposure of interest was the TB bacteriologic test status at the time of TB treatment initiation: *Positive test* group included patients with one or more positive results including acid fast bacilli (AFB) smear, culture, or NAAT; *Negative test* group included patients for whom one or more of these bacteriologic tests were performed and none were positive; *No test* group includes patients for whom no bacteriologic test was performed or results reported [34]. Patient-level variables at TB treatment initiation included: age, sex, body mass index (BMI), ART status at TB treatment initiation (on ART vs. not on ART), CD4 count (defined as the nearest value within 180 days before or 30 days after TB treatment initiation), TB disease site (pulmonary vs. extrapulmonary, and specific extrapulmonary site(s)), and type of bacteriologic TB test (smear, culture, NAAT; the specimen type [e.g. respiratory vs. non-respiratory] was not available). TB disease site was categorized into pulmonary and extrapulmonary according to the WHO and CDC reporting definitions [32, 34, 35]. Accordingly, pulmonary TB included any case involving the lung parenchyma or tracheobronchial tree, and miliary TB with lesions in the lungs; extrapulmonary TB included cases involving organs other than the lungs; cases of combined pulmonary and extrapulmonary TB were classified as pulmonary TB.

Site-level variables included IeDEA region (CCASAnet, Central Africa, East Africa, West

Africa), setting (urban, peri-urban [i.e. immediately adjoining urban areas], facility level (secondary [i.e district or provincial facilities] or tertiary [i.e regional or referral facilities]), availability of specialized clinic/ward on site with dedicated staff for TB patients (on site, off site, or not available), physical proximity of HIV/TB clinical services (same facility or same day appointments, cross referral between HIV and TB service points, provision of TB and HIV services under the same roof, or none of these models), and active screening for TB performed for all PLWH at enrollment (only symptom screening, symptom screening plus additional diagnostics, or in case of clinical suspicion). Site-level variables were applied to each patient within the site as an individual characteristic. The main outcome variable was death. Patients were followed from TB treatment initiation until death or censoring within the 12 months post-treatment initiation or June 1, 2015. All the non-death events within the 12 months of follow-up were considered censored events.

Data analysis

Patient characteristics were summarized overall and by each bacteriologic test group. Categorical variables were summarized using frequencies and proportions; continuous variables were summarized using medians and interquartile ranges. Differences between bacteriologic test groups were assessed using one-way ANOVA or Kruskal-Wallis tests for continuous variables and Pearson Chi-squared test or Fisher's exact tests for categorical variables. Cumulative incidence of survival, stratified by bacteriologic test group, was estimated using the Kaplan-Meier method. The log-rank test was used for testing equality of survival among the levels of categorical covariates. The Cox proportional hazard model was used to estimate the univariate and multivariate associations of covariates and the hazard for death. Independent variables

included in this model were sex, age, BMI, CD4 count, ART status at TB treatment initiation, TB disease site, leDEA region, and facility level. These variables were selected a priori because of their associations with adverse TB treatment outcomes in prior studies [21, 36-44]. The other site variables were not included in the model due to co-linearity with each other and the facility level variable.

The proportional hazards assumption was assessed using the supremum-type goodness of fit test. The impact of missingness on the observed hazard associations was assessed by refitting the models after imputing missing covariate values. In this analysis, missing values for CD4 count, BMI, and ART status at TB treatment initiation were multiply imputed using the fully conditional specification (FCS), where these covariates were assumed to be jointly distributed [45]. We did not impute missing values for cases with missing facility level, TB disease site, or simultaneously missing BMI, ART status, and CD4 count. Imputation followed Rubin's scheme: missing values were imputed 100 times; Cox proportional hazards models were fit for the 100 complete datasets; and, results were pooled to obtain overall effect estimates [46, 47]. Imputation analysis was performed using the PROC MI procedure in SAS [48]. Analyses were performed at the 0.05 alpha level.

In a secondary analysis comparing the hazard for death among those with any bacteriologic test (positive or negative) vs. no test results, we used logistic regression to build a propensity score model for the log odds of having any bacteriologic test given imbalance of covariates in the test groups (i.e. any test vs. no test). The independent variables included in this model were the same as those used in the primary analysis. Missing values for CD4 count, BMI, and ART status were

also multiply imputed. The imputation and propensity model were performed as follows: 1) missing values were imputed separately for those with and without a bacteriologic test; 2) propensity model was fit; 3) stabilized inverse probability weights (IPWs) were constructed using the predicted propensities, checking if the mean of weights was close to one (S3 Table); 4) the proportional hazards model was fit for time to death conditional on having any bacteriologic test, weighted by the IPWs to obtain an estimate of log hazards ratio and its robust standard error estimate. These steps were repeated 100 times and the resulting log-hazards ratio estimates and their standard errors pooled using Rubin's rules.

Results

Patient and site-level characteristics

Among 2,140 patients in the database, a total of 49 were excluded for initiating TB treatment outside of the study period (n=32) or before the TB diagnosis date (n=1), documentation errors (n=13), and receiving TB treatment regimens for drug-resistant TB (n=3). Thus, 2,091 patients were included in the analysis. These patients received care in 12 countries in the four participating IeDEA regions (Fig 1).

Fig 1. Patients included in the analysis by IeDEA region and country. Numbers in parentheses indicate the number of patients contributed by participating IeDEA programs in each country. Map created in January 2019 by John Humphrey using Tableau Public 2018.3.2 (Tableau Software, Seattle, WA).

A total of 615 (29%) had positive bacteriologic tests for TB, 907 (43%) had negative tests, and 569 (27%) had no test results (Table 1). The median age was 36 years, 44% were female, and the median BMI was 19 kg/m². Overall, 52% were on ART at TB treatment initiation, and the

proportions of patients in each bacteriologic test group who were on ART at TB treatment initiation were: positive test (56%), negative test (52%), and no TB test results (38%) ($P = 0.069$). The CD4 count was ≤ 200 cells/mm³ in 53% of patients. A total of 79% had pulmonary TB and 20% had extrapulmonary TB; the TB disease site was not specified in 1% of patients. The proportions of patients with extrapulmonary TB were significantly different between the three bacteriologic groups, with extrapulmonary TB in 35% of patients with no TB test result, compared to 8% of patients with a positive test and 19% with a negative test ($P < 0.001$). The most commonly reported extrapulmonary sites were bone and joint (34%) and pleura (22%).

Table 1. Patient characteristics stratified by TB bacteriologic test status.

Characteristic	Bacteriologic Test Status				P value ^a
	Total <i>N</i> = 2091 n (%)	Positive test <i>N</i> = 615 n (%)	Negative test <i>N</i> = 907 n (%)	No test result <i>N</i> = 569 n (%)	
Age, median years (IQR)	36 (30-43)	35 (30-42)	36 (30-43)	36 (29-44)	0.779
Female sex	910 (44)	266 (43)	385 (42)	259 (46)	0.505
BMI, median mg/kg ² (IQR)	19 (17-21)	19 (17-21)	19 (17-21)	20 (17-22)	0.001
Missing	374 (18)	86 (14)	89 (10)	199 (35)	
ART status at TB treatment initiation					0.069
On ART	1084 (52)	346 (56)	475 (52)	216 (38)	
Not on ART	790 (38)	215 (35)	359 (40)	263 (46)	
Missing	217 (10)	54 (9)	73 (8)	90 (16)	
CD4 count, cells/mm ³					0.612
< 100	716 (34)	204 (33)	309 (34)	203 (36)	
100-200	391 (19)	114 (19)	174 (19)	103 (18)	
201-350	306 (14)	85 (14)	148 (16)	73 (13)	
351-500	161 (8)	44 (7)	73 (8)	44 (8)	
> 500	118 (6)	36 (6)	59 (7)	23 (4)	
Missing	399 (19)	132 (21)	144 (16)	123 (21)	
TB disease site ^b					<0.001
Pulmonary	1646 (79)	564 (92)	732 (81)	350 (62)	
Miliary	18 (1)	0 (0)	13 (2)	5 (1)	0.011
Extrapulmonary	422 (20)	49 (8)	172 (19)	201 (35)	
Pleural	79 (22)	3 (10)	36 (23)	40 (20)	<0.001
Lymphatic	73 (20)	20 (67)	26 (17)	27 (13)	0.149
Bone and/or joint	12 (34)	1 (3)	5 (3)	6 (3)	0.129
Abdominal ^c	34 (10)	3 (10)	18 (11)	13 (7)	0.027
Pericardial	7 (2)	0 (0)	4 (3)	3 (2)	0.276
Genitourinary	1 (<1)	1 (3)	0 (0)	0 (0)	0.566

CNS and/or meningeal	21 (6)	1 (3)	13 (8)	7 (3)	0.042
Laryngeal	1 (<1)	0 (0)	1 (1)	0 (0)	1.000
Other	25 (7)	0 (0)	11 (7)	14 (7)	<0.001
Not specified	23 (1)	2 (<1)	3 (<1)	18 (3)	<0.001

ART, antiretroviral treatment; BMI, body mass index; CNS, central nervous system; IQR, interquartile range; TB, tuberculosis

^a P values comparing the three groups were calculated using ANOVA F-test, chi-square test, Kruskal-Wallis test, and Fisher's exact test.

^b Percentages of extrapulmonary sites refer to the total extrapulmonary sites; each patient could have > 1 extrapulmonary site.

^c Includes peritoneum, omentum, liver, spleen, and colon.

The East Africa IeDEA region contributed 72% of patients overall (Table 2). In this region, twice as many patients had a negative bacteriologic test (n=734) compared to a positive test (n=397) or no test (n=380). In contrast, more than twice as many patients in West Africa had either a positive (n=40) or negative test (n=52) compared to no test (n=19). Overall, more patients attended facilities that were peri-urban (47%) than urban (26%) or rural (23%). Among rural facilities, more patients had a negative test (n=324) than either a positive test (n=84) or no test results (72). A total of 88% of patients overall attended tertiary facilities, and there were more patients attending these facilities in the group with negative tests (n=812) than the groups with positive tests (n=472) or no test results (n=485). Finally, 93% of patients attended facilities with a specialized TB clinic/ward available on site, 69% attended facilities with same facility or same day HIV/TB service appointments, and 81% attended facilities with active screening for TB among all PLWH at enrollment that included symptom screening plus additional diagnostics. Site-level differences between the three test groups were significant for all characteristics measured ($P < 0.001$ for all).

Table 2. Patient distribution by site characteristics, stratified by TB bacteriologic test status.

Characteristic	Bacteriologic Test Status				P value ^a
	Total N = 2091 n (%)	Positive test N = 615 n (%)	Negative test N = 907 n (%)	No test N = 569 n (%)	
IeDEA region					<0.001
CCASAnet	313 (15)	126 (21)	77 (8)	110 (19)	
Central Africa	156 (8)	52 (8)	44 (5)	60 (11)	
East Africa	1511 (72)	397 (64)	734 (81)	380 (67)	
West Africa	111 (5)	40 (7)	52 (6)	19 (3)	
Setting					<0.001
Urban	537 (26)	198 (32)	151 (17)	188 (33)	
Peri-urban	986 (47)	286 (46)	393 (43)	307 (54)	
Rural	480 (23)	84 (14)	324 (36)	72 (13)	
Missing	88 (4)	47 (8)	39 (4)	2 (<1)	
Facility level					<0.001
Secondary	234 (12)	96 (15)	56 (6)	82 (14)	
Tertiary	1769 (88)	472 (77)	812 (90)	485 (85)	
Missing	88 (4)	47 (8)	39 (4)	2 (<1)	
Specialized TB clinic/ward on site					<0.001
Yes, on site	1951 (93)	550 (89)	858 (95)	543 (95)	
Yes, off site / by referral	20 (1)	3 (<1)	5 (<1)	12 (2)	
Not available	32 (2)	15 (2)	5 (<1)	12 (2)	
Missing	88 (4)	47 (8)	39 (4)	2 (<1)	
Physical proximity of HIV/TB services					<0.001
Same facility or same day appointments	1440 (69)	341 (55)	709 (78)	390 (69)	
Cross referral between HIV and TB service points	401 (19)	158 (26)	84 (9)	159 (28)	
Provision of TB and HIV services under the same roof	114 (5)	52 (8)	44 (5)	18 (3)	
None of these models	48 (2)	17 (3)	31 (3)	0 (0)	
Missing	88 (4)	47 (8)	39 (4)	2 (<1)	
Active screening for TB for all PLWH at enrollment					<0.001
All, but only symptom screening	199 (10)	91 (15)	32 (4)	76 (13)	
All, symptom screening plus additional diagnostics ^b	1689 (81)	425 (69)	785 (86)	479 (84)	
In case of clinical suspicion	115 (5)	52 (8)	51 (6)	12 (2)	
Missing	88 (4)	47 (8)	39 (4)	2 (<1)	

CCASAnet, Caribbean, Central and South America; PLWH, people living with HIV; TB, tuberculosis

^a ANOVA F-test, chi-square test, Kruskal-Wallis test, Fisher's exact test performed for each variable as appropriate.

^b Additional testing examples include sputum AFB, sputum induction, gastric lavage, tissue biopsy, chest x-ray, gene x-pert, urine lipoarabinomannan (LAM), tuberculin skin testing.

AFB smear was performed in 71% of patients (1,493 of 2,091) (Table 3). Culture and NAAT were performed in 8% and 3% of patients, respectively. Among 618 patients with a positive test (whereby ≥ 1 test type may be performed for each patient), 90% had a positive AFB smear, 16% had a positive culture, and 6% had a positive NAAT. Among 907 patients with a negative test (also including ≥ 1 test type), 99% had a negative AFB smear, 6% had a negative culture, and 3% had a negative NAAT. Among patients who had results from more than one test type reported, 75% with a positive AFB smear also had a positive culture (64 of 85) and 35% with a negative AFB smear also had a positive culture (27 of 78) (S4 Table). Among those who had AFB smear and NAAT results reported, 63% with a positive smear had a positive NAAT (10 of 16) and 38% with a negative smear had a positive NAAT (14 of 37).

Table 3. Summary of bacteriologic test results.

Characteristic	Bacteriologic Test Status		
	Total tests <i>N</i> = 2091 n (%)	Positive test <i>N</i> = 615 n (%)	Negative test <i>N</i> = 907 n (%)
AFB smear			
Positive	553 (26)	553 (90)	0 (0)
Negative	940 (45)	41 (7)	899 (99)
Not performed / no result	598 (29)	21 (3)	8 (1)
Culture			
Positive	98 (5)	98 (16)	0 (0)
Negative	75 (4)	22 (4)	53 (6)
Not performed / no result	1918 (91)	495 (80)	854 (94)
Nucleic acid amplification			
Positive	38 (2)	38 (6)	0 (0)
Negative	34 (2)	11 (2)	23 (3)
Not performed / no result	2019 (96)	566 (92)	884 (97)

AFB, acid-fast bacilli

Mortality outcome

A total of 243 (12%) deaths were reported in the study cohort: 64 (10%) deaths among those with a positive test, 99 (11%) among those with a negative test, and 80 (14%) in those with no test results ($P = 0.099$). The ordering of the survival function in the Kaplan-Meier curve suggested a significant difference in the cumulative incidence of survival between the three bacteriologic test groups. ($P = 0.017$) (Fig 2).

Fig 2. Cumulative incidence of survival after TB treatment initiation, stratified by TB bacteriologic test status. Red, positive test group; blue, negative test group; grey, no test result group.

Complete case analyses

In the unadjusted and adjusted complete case analyses (adjusted for age, sex, BMI, ART status at TB treatment initiation, CD4 count, TB disease site, region, and facility level), the hazards of death were not significantly higher for those treated for TB with no TB bacteriologic test results (adjusted HR [aHR] 0.87, 95% CI 0.49-1.55) or negative TB tests (aHR 1.19, 95% CI 0.73-1.93) compared to those with positive tests (Table 4). Factors significantly associated with a lower hazard for death in the unadjusted and adjusted analyses included being on ART at TB treatment initiation (aHR 0.57, 95% CI 0.39-0.84) and having a higher CD4 count at TB treatment initiation (e.g. compared to those with CD4 count < 100 cells/mm³, the aHR for death among those with a CD4 count of 100-200 cells/mm³ was 0.39, 95% CI 0.23-0.65).

Table 4. Hazard ratios for death within 12 months following TB treatment initiation.

Characteristic	Complete Case Analysis ^a		Multiple Imputation Analysis ^b	
	Unadjusted HR	Adjusted HR ^c	Unadjusted HR	Adjusted HR ^c
	<i>N</i> = 1258 HR (95% CI)	<i>N</i> = 1258 HR (95% CI)	<i>N</i> = 1953 HR (95% CI)	<i>N</i> = 1953 HR (95% CI)
Bacteriologic Test				
Positive	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
Negative	1.34 (0.86-2.09)	1.19 (0.73-1.93)	1.18 (0.85-1.64)	1.28 (0.91-1.81)
None	1.21 (0.70-2.08)	0.87 (0.49-1.55)	1.57 (1.11-2.23)	1.56 (1.08-2.26)
Age (years)	1.01 (0.99-1.03)	1.01 (0.99-1.02)	1.02 (1.004-1.03)	1.02 (1.003-1.03)
Sex				
Female	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
Male	1.23 (0.85-1.78)	1.15 (0.78-1.69)	1.24 (0.95-1.63)	1.20 (0.91-1.59)
BMI (mg/kg²)	0.97 (0.92-1.02)	0.98 (0.92-1.03)	0.97 (0.93-1.01)	0.97 (0.93-1.002)
ART status at TB treatment initiation				
Not on ART	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
On ART	0.63 (0.44-0.91)	0.57 (0.39-0.84)	0.64 (0.48-0.85)	0.61 (0.47-0.80)
CD4 count				
< 100	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
100-200	0.39 (0.23-0.66)	0.39 (0.23-0.65)	0.66 (0.46-0.95)	0.69 (0.49-0.97)
201-350	0.44 (0.26-0.75)	0.42 (0.24-0.71)	0.56 (0.37-0.85)	0.56 (0.38-0.81)
351-500	0.16 (0.05-0.51)	0.15 (0.05-0.48)	0.47 (0.25-0.87)	0.46 (0.27-0.79)
> 500	0.21 (0.07-0.66)	0.19 (0.06-0.62)	0.26 (0.10-0.68)	0.27 (0.12-0.64)
TB disease site				
Pulmonary	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
Extrapulmonary	1.10 (0.70-1.72)	1.10 (0.68-1.76)	1.21 (0.88-1.64)	1.09 (0.79-1.51)
IeDEA Region				
CCASAnet	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
Central Africa	1.04 (0.36-3.01)	1.08 (0.35-3.33)	0.92 (0.53-1.62)	0.52 (0.27-1.02)
East Africa	0.97 (0.52-1.81)	0.98 (0.49-1.96)	0.81 (0.58-1.13)	0.77 (0.54-1.11)
West Africa	1.51 (0.62-3.64)	0.89 (0.25-3.22)	1.06 (0.53-2.10)	0.38 (0.16-0.91)
Facility level				
Secondary	1 (Ref.)	1 (Ref.)	1 (Ref.)	1 (Ref.)
Tertiary	0.69 (0.40-1.18)	0.63 (0.27-1.47)	0.61 (0.43-0.88)	0.41 (0.25-0.67)

ART, antiretroviral treatment; BMI, body mass index; CCASAnet, Caribbean, Central and South America; HR, hazard ratio; CI, confidence interval; Ref., reference; TB, tuberculosis

^a Includes all patients without missing values for the variables listed in the table.

^b Missing values were imputed for CD4 count, BMI, and ART status at TB treatment initiation. This model includes all patients without missing values for the variables listed in the table, including those for whom CD4, BMI, and ART status was imputed.

^c Adjusted for all of the variables listed in the table.

Multiple imputation analyses

Of 2,091 patients in the study, 1,258 (60%) were complete cases with respect to the analysis model. Of the 833 subjects with missing values, we did not perform imputation for 138 cases. Thus, each imputed dataset had 1,953 subjects. After imputation of missing CD4 count, BMI, and ART status at TB treatment initiation, the unadjusted multiple imputation analysis showed that the hazard for death was significantly higher among those with no test result compared to those with a positive test (HR 1.57, 95% CI 1.11-2.23) (Table 4). In this analysis, older age was significantly associated with a higher hazard for death (HR 1.02, 95% CI 1.004-1.03). Factors significantly associated with a lower hazard for death included being on ART at TB treatment initiation (HR 0.64, 95% CI 0.48-0.85), having a higher CD4 count (e.g. HR for those with CD4 count of 100-200 cells/mm³ was 0.66, 95% CI 0.46-0.95), and tertiary facility level (HR 0.61, 95% CI 0.43-0.88). In the adjusted analysis (adjusted the same covariates as in the complete case analysis), the hazard for death was significantly associated with having no test result compared to a positive test (aHR 1.56, 95% CI 1.08-2.26), and there was no difference between those with a positive test and negative test (aHR 1.28, 95% CI 0.91-1.81). Similar to the unadjusted analysis, factors associated with a lower hazard for death included being on ART at TB treatment initiation, having a higher CD4 count and tertiary facility level, as well as West Africa IeDEA region (aHR 0.38, 95% CI 0.16-0.91).

Secondary analysis

The propensity model for the log-odds of having any bacteriologic test (positive or negative) vs. no test result demonstrated that CD4 count, BMI, TB disease site, facility level, and IeDEA region were each associated with the log odds of having a test (S5 Table). In the odds ratio scale,

the adjusted odds of having any test among those with extrapulmonary TB, for example, was 45% lower than the odds for those with pulmonary TB ($P < 0.0001$) (S6 Table). This model was used to estimate the propensity scores, which were in turn used to compute the stabilized IPWs. For each of the 100 analyses combining multiple imputation and propensity score analysis, the stabilized IPWs were found to have an average close to 1. The stabilized IPWs were then used in fitting 100 adjusted Cox models for time to death conditional on whether or not a bacteriologic test had been performed (i.e. test vs. no test). The pooled results for the IPW proportional hazards models demonstrated that the adjusted hazard for death was 28% lower among those with any bacteriologic test compared to those with no test results, but the effect was not significant at the 0.05 alpha level (aHR 0.81, 95% CI 0.61-1.07) (S7 Table).

Discussion

In this study, PLWH treated for TB in our cohorts in the absence of TB bacteriologic test results had a higher adjusted hazard for death than those treated for TB with positive TB bacteriologic test results. Unlike those with bacteriologically confirmed TB disease (i.e. the positive test group), it is plausible that those with no bacteriologic test results were a heterogeneous population of individuals with TB as well as other life-threatening diseases (e.g. opportunistic infections, cancers, chronic lung diseases) that may have mimicked TB but advanced untreated while the patient received TB treatment, resulting in excess mortality. This, along with the 12-month mortality outcome, suggests that not all patients who initiated TB treatment had TB disease and not all deaths were TB-attributable.

Differences in TB disease site or severity between those with positive and no test results may also have influenced mortality. As expected, the proportion of patients with pulmonary TB was higher among those with positive tests (92%) compared to those with no test results (62%) ($P < 0.001$). This reflects the challenge of acquiring a bacteriologic diagnosis in suspected extrapulmonary TB (which often requires invasive tissue sampling) compared to pulmonary TB (which requires sputum sampling) in resource-constrained settings. Additionally, bacteriologic testing for extrapulmonary TB is less sensitive in general compared to pulmonary TB, extrapulmonary TB is more common in PLWH, certain extrapulmonary TB types (e.g. disseminated or meningitis) are associated with especially high mortality in PLWH, and extrapulmonary TB has been associated with delays in diagnosis [40, 42, 43, 49-52]. These features may also have influenced clinicians to forego bacteriologic testing and initiate empiric TB treatment among individuals that were already at increased risk of death. TB disease site was not associated with mortality in our analyses, but we could not account for group variability in extrapulmonary TB sites that may have influenced this outcome.

We also found that PLWH attending tertiary facilities had a lower adjusted hazard for death compared to those attending secondary facilities. Compared to tertiary facilities, secondary facilities may have had less capacity to evaluate and manage TB, or its alternative diagnoses, in PLWH [53]. This finding may also have been biased by differences in the completeness of death ascertainment between higher and lower-resourced facilities, the latter being potentially more susceptible to undocumented loss to follow-up or transfer events not captured in our dataset [54]. Differences in vital status ascertainment may also have accounted for the regional differences in the hazards for death (West Africa vs. CCASAnet) identified in our study.

Consistent with the literature, we found that being on ART and having higher CD4 count at TB treatment initiation were both strongly protective against mortality. This underscores the fundamental importance of early ART initiation and immune preservation on survival, regardless of the presence or result of TB bacteriologic testing, in resource-constrained settings. Advanced HIV immunosuppression is known to be a critical risk factor for TB-related mortality (including mortality ≥ 1 year after completion of TB therapy), and the scale-up of ART coverage has been associated with marked reductions in TB incidence and mortality in countries with high HIV and TB burdens [20, 21, 40, 41, 55-57].

We did not find a significant difference in the adjusted hazard for death between those treated for TB with any bacteriologic test (positive or negative) versus no test results in the secondary analysis. This finding is consistent with a study in Brazil which found no difference in mortality risk between PLWH who did or did not undergo TB bacteriologic testing [17]. This argues against the notion that the presence of TB bacteriologic testing is a marker of better-resourced sites (and therefore reduced mortality), as patients with a bacteriologic test would have been expected to have a lower mortality than those who were not tested if that were the case. It is possible that patients in both groups had similar survival simply by being engaged in facility-based care.

Finally, we found no significant difference in the hazard for death between those with positive or negative TB bacteriologic tests (Fig 2 and Table 3). This lack of significance may in part be related to limited statistical power, as the adjusted hazard for death in those with negative tests

was similar to that for those with no test results (aHR 1.28 vs. 1.56). Nevertheless, this finding contrasts with prior studies finding that smear-negative TB is associated with increased mortality compared to smear-positive TB in PLWH. This finding has been attributed to paucibacillary disease in the setting of advanced HIV, delay in diagnosis, and other opportunistic and non-communicable diseases [14, 21-23, 58-65]. Similar findings have been shown with respect to culture results among PLWH treated for TB, but no such studies have been performed for NAAT to our knowledge [66]. The lack of mortality difference in our study could also be related to the combination of smear, culture, and NAAT used to define the groups, overdiagnosis of TB in the negative test group (yielding lower than expected mortality), or higher bacterial burden due to more extensive TB disease or inadequate treatment of drug-resistant TB in the positive test group (yielding higher than expected mortality) [67]. The 12-month mortality outcome used in our study, which was selected due to limitations in the dataset, may also have influenced this finding. A study from the Democratic Republic of Congo, for example, found that patients treated for smear-negative TB had a higher risk of death within two months of TB treatment initiation, but not after, compared to those treated for smear-positive TB [62].

Our study has strengths and limitations. Strengths include its large sample size from diverse global regions and HIV/TB care programs and use of routine program data which likely reflects typical care environments in the study settings. The use of routine program data is also a limitation, as the completeness of vital status ascertainment may have been affected by loss to follow-up or transfer events not captured in our dataset. We cannot be certain that patients with no TB bacteriologic test results documented in their records did not actually have testing performed. Still, the integration of TB-HIV services at the majority of sites supports that TB test

results would have been recorded in the medical records and case report forms if they were available. Few patients had culture or NAAT performed, which limits the generalizability of our study in settings where these tests are performed more commonly. We used multiple imputation to reduce bias due to missing data, but the mortality estimate could still be biased if missingness depended not only on the variables we used to impute missing values but also on the missing values themselves (i.e., missing not at random).

In conclusion, PLWH treated for TB with no TB bacteriologic test results in our study were more likely to die than those who were treated and had positive tests. Every effort should be made to establish a diagnosis of TB prior to initiating TB treatment in resource-constrained settings. Further research is needed to understand the causes of death among PLWH treated for TB in the absence of positive bacteriologic test results.

Acknowledgements

We are grateful for the participation of the following IeDEA Collaborative sites: Brazil – INI-Fiocruz; Burundi – CPAMP-CHUK; Côte d'Ivoire – Centre Intégré de Recherches Biocliniques d'Abidjan (CIRBA), Centre Hospitalier Universitaire de Cocody, CREF/SMIT, Medicine Interne; Honduras - IHHS; Kenya –AMPATH; Mexico - INCMNSZ; Peru – IMTAvH, CoVIHS; République Démocratique du Congo – Bomo Health Centre, Kalembelembe Paediatric Hospital; Rwanda – Rwanda Military Hospital; Tanzania – National AIDS Control Programme, Tumbi Regional Hospital, National Institute for Medical Research, Mwanza Research Centre-Kisesa

417 Clinic; Uganda – Masaka Regional Hospital. A complete listing of participating programs and
418 members can be found in S8 Table.

References

1. World Health Organisation. Global Tuberculosis Report 2018. Geneva; 2018.
2. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. *AIDS*. 2015;29(15):1987-2002.
3. Auld AF, Fielding KL, Gupta-Wright A, Lawn SD. Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials? *Trans R Soc Trop Med Hyg*. 2016;110(8):432-44.
4. Clouse K, Blevins M, Lindegren ML, Yotebieng M, Nguyen DT, Omondi A, et al. Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program. *PLoS One*. 2017;12(2):e0171384.
5. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. *Lancet*. 2014;383(9915):424-35.
6. Onyebujoh PC, Thirumala AK, Piatek A. Stronger tuberculosis laboratory networks and services in Africa essential to ending tuberculosis. *Afr J Lab Med*. 2017;6(2):519.
7. World Health Organisation. Global Tuberculosis Control 2011. Geneva; 2011.
8. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. *Clin Microbiol Rev*. 2011;24(2):314-50.
9. Zumla A, Petersen E, Nyirenda T, Chakaya J. Tackling the tuberculosis epidemic in sub-Saharan Africa-unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. *Int J Infect Dis*. 2015;32:46-9.
10. Loveday M, Thomson L, Chopra M, Ndlela Z. A health systems assessment of the KwaZulu-Natal tuberculosis programme in the context of increasing drug resistance. *Int J Tuberc Lung Dis*. 2008;12(9):1042-7.
11. Van Deun A, Salim AH, Cooreman E, Hossain MA, Rema A, Chambugonj N, et al. Optimal tuberculosis case detection by direct sputum smear microscopy: how much better is more? *Int J Tuberc Lung Dis*. 2002;6(3):222-30.
12. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. *Lancet*. 2011;377(9776):1495-505.
13. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extra-pulmonary tuberculosis among adults and adolescents: Recommendations for HIV-prevalent and resource-constrained settings. Geneva; 2007.
14. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *Lancet*. 2007;369(9578):2042-9.

15. Roy M, Muyindike W, Vijayan T, Kanyesigye M, Bwana M, Wenger M, et al. Implementation and Operational Research: Use of Symptom Screening and Sputum Microscopy Testing for Active Tuberculosis Case Detection Among HIV-Infected Patients in Real-World Clinical Practice in Uganda. *J Acquir Immune Defic Syndr*. 2016;72(5):e86-91.
16. Elbireer AM OA, Brough RL, Brooks Jackson J, Manabe YC. Strengthening Public Laboratory Service in Sub-Saharan Africa: Uganda Case Study. *Lab Med*. 2011;42(12):719-25.
17. Albuquerque Mde F, Coimbra I, Batista J, Maruza M, Ximenes RA, Lacerda HR, et al. Empirical treatment for TB in HIV: lessons from a cohort study of people living with HIV treated in Recife, Brazil. *BMC Public Health*. 2014;14:289.
18. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendations for HIV-prevalence and resource-constrained settings. Geneva; 2007.
19. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. *PLoS One*. 2013;8(6):e65421.
20. Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, et al. Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. *Open Forum Infect Dis*. 2014;1(1):ofu038.
21. Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. *Int J Tuberc Lung Dis*. 2011;15(7):871-85.
22. Hargreaves NJ, Kadzakumanja O, Phiri S, Nyangulu DS, Salaniponi FM, Harries AD, et al. What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? *Int J Tuberc Lung Dis*. 2001;5(2):113-22.
23. Hargreaves NJ, Kadzakumanja O, Whitty CJ, Salaniponi FM, Harries AD, Squire SB. 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. *Int J Tuberc Lung Dis*. 2001;5(9):847-54.
24. Campos LC, Rocha MV, Willers DM, Silva DR. Characteristics of Patients with Smear-Negative Pulmonary Tuberculosis (TB) in a Region with High TB and HIV Prevalence. *PLoS One*. 2016;11(1):e0147933.
25. International Epidemiology Databases to Evaluate AIDS (IeDEA) [Internet]. 2018 [Cited 31 January 2019]. Available from: <https://www.iedea.org>.
26. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. *Int J Epidemiol*. 2012;41(5):1256-64.
27. World Health Organization. Treatment of tuberculosis: guidelines – 4th ed. Geneva; 2010.
28. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61(4):344-9.

- 495 29. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
496 (REDCap)--a metadata-driven methodology and workflow process for providing translational research
497 informatics support. J Biomed Inform. 2009;42(2):377-81.
- 498 30. Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, et al. Implementation of
499 Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's")
500 and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One.
501 2016;11(4):e0153243.
- 502 31. Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, et al. Tuberculosis in antiretroviral
503 treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS
504 One. 2013;8(10):e77697.
- 505 32. World Health Organization. Global Tuberculosis Report 2017. Geneva; 2017.
- 506 33. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of
507 Disease Study 2015. Lancet Infect Dis. 2018;18(3):261-84.
- 508 34. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision.
509 Geneva; 2013.
- 510 35. Centers for Disease Control and Prevention (CDC). *Reported Tuberculosis in the United States, 2016*.
511 Atlanta, GA: US Department of Health and Human Services, CDC; 2017.
- 512 36. Teklu AM, Nega A, Mamuye AT, Sitotaw Y, Kassa D, Mesfin G, et al. Factors Associated with
513 Mortality of TB/HIV Co-infected Patients in Ethiopia. Ethiop J Health Sci. 2017;27(Suppl 1):29-38.
- 514 37. Dawood H, Hassan-Moosa R, Zuma NY, Naidoo K. Mortality and treatment response amongst HIV-
515 infected patients 50 years and older accessing antiretroviral services in South Africa. BMC Infect Dis.
516 2018;18(1):168.
- 517 38. Lindan CP, Allen S, Serufulira A, Lifson AR, Van de Perre P, Chen-Rundle A, et al. Predictors of
518 mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med. 1992;116(4):320-8.
- 519 39. Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Farnia P, Marjani M, et al. Treatment outcome, mortality
520 and their predictors among HIV-associated tuberculosis patients. Int J STD AIDS. 2012;23(9):e1-4.
- 521 40. Schmaltz CA, Santoro-Lopes G, Lourenco MC, Morgado MG, Velasque Lde S, Rolla VC. Factors
522 impacting early mortality in tuberculosis/HIV patients: differences between subjects naive to and
523 previously started on HAART. PLoS One. 2012;7(9):e45704.
- 524 41. Mugusi FM, Mehta S, Villamor E, Urassa W, Saathoff E, Bosch RJ, et al. Factors associated with
525 mortality in HIV-infected and uninfected patients with pulmonary tuberculosis. BMC Public Health.
526 2009;9:409.
- 527 42. Kourbatova EV, Leonard MK, Jr., Romero J, Kraft C, del Rio C, Blumberg HM. Risk factors for
528 mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US.
529 Eur J Epidemiol. 2006;21(9):715-21.
- 530 43. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatittham W, Akksilp S, et al. HIV-
531 associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. Int J Infect
532 Dis. 2009;13(6):722-9.

- 533 44. Dangisso MH, Datiko DG, Lindtjorn B. Trends of tuberculosis case notification and treatment outcomes
534 in the Sidama Zone, southern Ethiopia: ten-year retrospective trend analysis in urban-rural settings.
535 PLoS One. 2014;9(12):e114225.
- 536 45. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification.
537 Stat Methods Med Res. 2007;16(3):219-42.
- 538 46. Rubin DB. Inference and missing data. Biometrika. 1976;63(3):581-92.
- 539 47. Rubin DB. Multiple imputation for nonresponse in surveys: John Wiley & Sons; 2004.
- 540 48. The MI Procedure: SAS/STAT 14.1 User's Guide; 2008. Available from:
541 <https://support.sas.com/documentation/onlinedoc/stat/141/mi.pdf>.
- 542 49. Qian X, Nguyen DT, Lyu J, Albers AE, Bi X, Graviss EA. Risk factors for extrapulmonary
543 dissemination of tuberculosis and associated mortality during treatment for extrapulmonary tuberculosis.
544 Emerg Microbes Infect. 2018;7(1):102.
- 545 50. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in
546 sub-Saharan Africa. AIDS. 2001;15(2):143-52.
- 547 51. El Sahly HM, Teeter LD, Pan X, Musser JM, Graviss EA. Mortality associated with central nervous
548 system tuberculosis. J Infect. 2007;55(6):502-9.
- 549 52. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of
550 tuberculosis. BMC Public Health. 2008;8:15.
- 551 53. Saito S, Howard AA, Reid MJ, Elul B, Scardigli A, Verkuijl S, et al. TB diagnostic capacity in sub-
552 Saharan African HIV care settings. J Acquir Immune Defic Syndr. 2012;61(2):216-20.
- 553 54. Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, et al. Loss to follow-up and mortality
554 among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir
555 Immune Defic Syndr. 2012;59(1):25-30.
- 556 55. Yan I, Bendavid E, Korenromp EL. Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in
557 High TB/HIV Burden Countries: An Econometric Analysis. PLoS One. 2016;11(8):e0160481.
- 558 56. Au-Yeung C, Kanters S, Ding E, Glaziou P, Anema A, Cooper CL, et al. Tuberculosis mortality in HIV-
559 infected individuals: a cross-national systematic assessment. Clin Epidemiol. 2011;3:21-9.
- 560 57. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for
561 prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med.
562 2012;9(7):e1001270.
- 563 58. Djouma FN, Noubom M, Ngomba AV, Donfack H, Kouomboua PS, Saah MA. Determinants of death
564 among tuberculosis patients in a semi urban diagnostic and treatment centre of Bafoussam, West
565 Cameroon: a retrospective case-control study. Pan Afr Med J. 2015;22:253.
- 566 59. Lawn SD, Acheampong JW. Pulmonary tuberculosis in adults: factors associated with mortality at a
567 Ghanaian teaching hospital. West Afr J Med. 1999;18(4):270-4.
- 568 60. Calis J, Bakker ML, Elens RB, Borgdorff M, Harries AD. Mortality in smear-negative tuberculosis
569 patients in Phalombe. Malawi Med J. 2002;14(2):13-4.

61. Harries AD, Nyirenda TE, Banerjee A, Boeree MJ, Salaniponi FM. Treatment outcome of patients with smear-negative and smear-positive pulmonary tuberculosis in the National Tuberculosis Control Programme, Malawi. *Trans R Soc Trop Med Hyg.* 1999;93(4):443-6.
62. Henegar C, Behets F, Vanden Driessche K, Tabala M, Bahati E, Bola V, et al. Mortality among tuberculosis patients in the Democratic Republic of Congo. *Int J Tuberc Lung Dis.* 2012;16(9):1199-204.
63. Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. *AIDS.* 1997;11 Suppl B:S115-23.
64. Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. *PLoS One.* 2017;12(11):e0188235.
65. Macpherson P, Dimairo M, Bandason T, Zezai A, Munyati SS, Butterworth AE, et al. Risk factors for mortality in smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe. *Int J Tuberc Lung Dis.* 2011;15(10):1390-6.
66. Crabtree-Ramírez BE JC, Jayathilake K, Carriquiry G, Veloso VG, Padgett D, Gotuzzo E, Cortes C, Mejia F, McGowan CC, Duda S, Shepherd B, Sterling TR. HIV-related tuberculosis: mortality risk in persons without vs. culture-confirmed disease. *Int J Tuberc Lung Dis.* Forthcoming 2019.
67. Zurcher K BM, Fenner L, Borrell S, Keller PM, Gnokoro J. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. *Lancet Infect Dis.* 2019 Feb 7. doi: 10.1016/S1473-3099(18)30673-X.

Supporting Information

S1 Table. STROBE checklist.

S2 Table. Independent Ethics Committee or Institutional Review Board approvals obtained by participating IeDEA sites.

S3 Table. Computation of stabilized inverse probability weights.

S4 Table. Summary of the number (%) of positive and negative bacteriologic test results in patients with more than one test type performed. (A) AFB smear + culture, (B) AFB smear + NAAT, (C) Culture + NAAT.

S5 Table. Propensity model results in the log of odds ratio scale.

S6 Table. Propensity model results in odds ratio scale.

S7 Table. Inverse probability weighted Cox proportional hazards model for hazard of death within 12 months following TB treatment initiation conditional on receiving a TB bacteriologic test (positive or negative). Includes imputation of CD4 count, body mass index (BMI), and antiretroviral treatment (ART) status at TB treatment initiation.

S8 Table: Membership of the International Epidemiology Databases to Evaluate AIDS (IeDEA) participating programs.





Fig 1



Bacteriologic
test group

Number at risk

Positive test	615	556	475	373	0
Negative test	907	810	705	524	3
No test	569	452	382	297	3

Fig 2